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Background: Previous reports have clearly indicated a significant relationship between hemoglobin (Hb) A1c change
from one visit to the next and microvascular complications, especially nephropathy (albuminuria and albuminuric
chronic kidney disease, CKD). In contrast, data on macrovascular disease are less clear. This study was aimed at
examining the association of HbA1c variability with cardiovascular disease (CVD) in the large cohort of subjects with
type 2 diabetes from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study.
Methods: Serial (3–5) HbA1c values obtained during the 2-year period preceding recruitment, including that obtained at
the enrolment, were available from 8,290 subjects from 9 centers (out of 15,773 patients from 19 centers). Average HbA1c
and HbA1c variability were calculated as the intra-individual mean (HbA1c-MEAN) and standard deviation (HbA1c-SD),
respectively, of 4.52±0.76 values. Prevalent CVD, total and by vascular bed, was assessed from medical history by
recording previous documented major acute events. Diabetic retinopathy (DR) was assessed by dilated fundoscopy. CKD
was defined based on albuminuria, as measured by immunonephelometry or immunoturbidimetry, and estimated
glomerular filtration rate, as calculated from serum creatinine.
Results: HbA1c-MEAN, but not HbA1c-SD, was significantly higher (P<0.0001) in subjects with history of any CVD (n. 2,133,
25.7%) than in those without CVD (n. 6,157, 74.3%). Median and interquartile range were 7.78 (7.04-8.56) and 7.49 (6.81-
8.31), respectively, for HbA1c-MEAN, and 0.47 (0.29-0.75) and 0.46 (0.28-0.73), respectively, for HbA1c-SD. Logistic regression
analyses showed that HbA1c-MEAN, but not HbA1c-SD (and independent of it), was a significant correlate of any CVD.
Similar findings were observed in subjects with versus those without any coronary or cerebrovascular event or myocardial
infarction. Conversely, none of these measures were associated with stroke, whereas both correlated with any lower limb
vascular event and HbA1c-SD alone with ulceration/gangrene. All these associations were independent of known CVD risk
factors and microvascular complications (DR and CKD).
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Conclusions: In patients with type 2 diabetes, HbA1c variability has not a major impact on macrovascular
complications, at variance with average HbA1c, an opposite finding as compared with microvascular disease, and
particularly nephropathy.
Trial registration: ClinicalTrials.Gov NCT00715481
Keywords: Chronic kidney disease, Retinopathy, Hemoglobin A1c, Risk factors, Type 2 diabetesBackground
Glycemic exposure, i.e. the extent and duration of
hyperglycemia, is a major risk factor for both micro and
macrovascular complications of diabetes. In fact, data
from subjects with type 1 and type 2 diabetes from the
Diabetes Control and Complications Trial (DCCT) and
the UK Prospective Diabetes Study, respectively, have
shown a strong association between exposure to hyper-
glycemia and diabetic complications [1,2] as well as a
significant benefit of intensive glycemic control on the
development and progression of microvascular disease
[3,4]. In addition, post-trial, prolonged follow-up has
uncovered a beneficial effect of prior intensive regimen
on cardiovascular disease (CVD) in both studies [5,6].
Though difference in average hemoglobin (Hb) A1c was
found to explain virtually all of the difference in risk of
complications between the intensive and conventional
groups in the DCCT [7], it is still under debate whether
or not variability of glycemic control has also a role.
Glycemic variability comprises “glucose variability” and
“HbA1c variability”. Glucose variability relates to within-
day fluctuations of glycemia, especially as a consequence of
post-prandial hyperglycemia [8], which may eventually re-
flect in HbA1c levels above the normal range. Conversely,
HbA1c variability relates to changes in glycemia over longer
periods of time, which result in change in HbA1c from one
visit to the next [9]. Several observational studies have
shown that post-prandial glucose, even in the range of im-
paired glucose tolerance, is a strong independent predictor
of CVD [10]. However, three retrospective analyses of the
DCCT found that within-day glucose variability does not
contribute to the development of microvascular complica-
tions [11-13]. Moreover, a prospective study specifically ad-
dressing this issue showed no effect of either post-prandial
glucose [14] or glucose variability [15] on CVD events,
though a post hoc subgroup analysis demonstrated lower
CVD risk in older patients targeting postprandial versus
fasting/pre-meal glycemia [16] and continuous glucose
monitoring showed that intraday glycemic variability is as-
sociated with the presence and severity of arterial lesions
in subjects with type 2 diabetes undergoing coronary angi-
ography for chest pain [17].
Conversely, robust evidence links HbA1c variability to
the risk of microvascular complications in both type 1
and type 2 diabetes. In fact, retrospective analyses of theDCCT [18] and the Finnish Diabetic Nephropathy
(FinnDiane) Study [19] have shown that change in HbA1c
from one visit to the next is an independent risk factor for
the development of both diabetic retinopathy (DR) and ne-
phropathy (DN) in individuals with type 1 diabetes. In
addition, HbA1c variability was shown to be an independent
variable that added to the effect of HbA1c on the risk of
microalbuminuria in adolescent patients with type 1 dia-
betes from the Oxford Regional Prospective Study and the
Nephropathy Family Study [20]. Very recently, two pro-
spective cohort studies from Japan and Taiwan, the
Tsukuba Kawai Diabetes Registry 2 [21] and the Diabetes
Management through an Integrated Delivery System pro-
ject [22], have shown that HbA1c variability is associated
with microalbuminuria in patients with type 2 diabetes
even after adjustment for known predictors of albuminuria.
These data are consistent with our recent report from the
Renal Insufficiency And Cardiovascular Events (RIACE)
Italian Multicenter Study that HbA1c variability is an inde-
pendent correlate of albuminuria and the albuminuric
phenotypes of chronic kidney disease (CKD), but not of
non-albuminuric CKD and DR [23].
However, data are less stringent with respect to the asso-
ciation of HbA1c variability with CVD. In type 1 diabetes,
HbA1c variability was predictive of incident CVD events
in the FinnDiane Study [19], whereas HbA1c variation (not
variability) over time showed a stronger association
with coronary artery disease than baseline values in the
Pittsburgh Epidemiology of Diabetes Complications Study
[24]. Recently, a prospective analysis of the Hong Kong
Diabetes Registry has shown that HbA1c variability is asso-
ciated with incident CKD and CVD, independent of aver-
age HbA1c and other confounding variables [25].
This analysis was aimed at assessing the independent as-
sociation of HbA1c variability with CVD, either total or by
vascular bed, in the large cohort of Caucasian subjects with
type 2 diabetes from the RIACE Italian Multicenter Study.
Methods
Study cohort
We used the data collected at the baseline visit for
the RIACE Italian Multicenter Study (registered with
ClinicalTrials.gov, NCT00715481; URL http://www.
clinicaltrials.gov/ct2/show/NCT00715481), an obser-
vational, prospective cohort study on the impact of
Table 1 CVD risk factors in study subjects
Variables CVD no CVD yes P
n (%) 6,157 (74.3) 2,133 (25.7)
Males (%) 3,300 (53.6) 1,426 (66.9) <0.0001
Age, years 66.4±10.0 69.6±9.3
<0.0001
67 (60–73) 70 (63–76)
Age at diabetes diagnosis,
years
52.0±10.6 51.2±10.9
0.003
52 (45–59) 51 (44–58)
Diabetes duration, years 14.5±10.0 18.4±10.4
<0.0001
12 (6–21) 18 (10–26)
Smoking, n (%) <0.0001
Never 3,478 (56.5) 1,006 (47.2)
Former 1,739 (28.2) 817 (38.3)
Current 940 (15.3) 310 (14.5)
Current HbA1c, % 7.57±1.36 7.86±1.40
<0.0001
7.42 (6.70-8.28) 7.66 (6.92-8.59)
HbA1c-MEAN, % 7.63±1.19 7.88±1.21
<0.0001
7.49 (6.81-8.31) 7.78 (7.04-8.56)
HbA1c-SD, % 0.59±0.48 0.60±0.47
0.105
0.46 (0.28-0.73) 0.47 (0.29-0.75)
HbA1c-CV, % 7.57±5.52 7.45±5.17
0.936
6.06 (3.94-9.37) 6.17 (3.96-9.33)
Adj-HbA1c-SD, % 0.52±0.42 0.53±0.41
0.058
0.40 (0.26-0.67) 0.42 (0.26-0.67)
BMI, kg/m2
Males 28.2±4.3 28.6±4.5
0.017
27.7 (25.2-30.6) 28.1 (25.4-31.0)
Females 29.4±5.7 29.5±5.8
0.820
28.7 (25.5-32.5) 28.8 (25.5-32.8)
Triglycerides, mmol/l 1.52±0.90 1.58±0.94
0.016
1.30 (0.95-1.83) 1.35 (0.98-1.92)
Total cholesterol, mmol/l 4.82±0.93 4.56±0.95
<0.0001
4.76 (4.20-5.39) 4.77 (3.91-5.12)
HDL cholesterol, mmol/l
Males 1.25±0.33 1.19±0.31
<0.0001
1.22 (1.01-1.45) 1.14 (0.97-1.35)
Females 1.41±0.37 1.33±0.33
<0.0001
1.35 (1.14-1.59) 1.28 (1.09-1.52)
LDL cholesterol, mmol/l 2.81±0.80 2.61±0.81
<0.0001
2.77 (2.36-4.01) 2.54 (2.05-3.07)
Non-HDL cholesterol, mmol/
l
3.50±0.90 3.33±0.90
<0.0001
3.42 (2.82-3.98) 3.22 (2.69-3.83)
Dyslipidemia, n (%) 5,032 (81.7) 1,871 (87.7) <0.0001
Systolic BP, mmHg 139.8±18.0 138.9±19.1
0.050
140 (130–150) 140 (125–150)
Table 1 CVD risk factors in study subjects (Continued)
Diastolic BP, mmHg 78.9±9.1 77.4±9.4
<0.0001
80 (71–85) 80 (70–82)
Hypertension, n (%) 5,121 (83.2) 1,987 (93.2) <0.0001
Prevalence of CVD risk factors in individuals with or without prior CVD event(s).
Values are mean±SD and median (interquartile range) for continuous variables
and n (%) for categorical variables; P values for comparison between groups
using the Student’s t test for parametric or the corresponding Mann–Whitney U
test for nonparametric (HbA1c-SD, HbA1c-CV, Adj- HbA1c-SD, and triglycerides)
continuous variables, and the χ2 test for categorical variables.
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bidity and mortality from CVD in type 2 diabetes.
The RIACE cohort consisted of 15,933 Caucasian pa-
tients with type 2 diabetes (defined by the American Dia-
betes Association criteria), attending consecutively 19
hospital-based Diabetes Clinics of the National Health
Service throughout Italy (see Additional file 1) in years
2007–2008. Exclusion criteria were dialysis or renal trans-
plantation. The study protocol was reviewed by the locally
appointed ethics boards. The quality and completeness of
data were controlled and 160 patients were excluded due
to missing or implausible values and the remaining 15,773
subjects were subsequently analyzed. Multiple HbA1c
values (3 to 5, mean±SD: 4.52±0.76) serially measured at
intervals of 6–12 months during the 2-year period preced-
ing the enrolment were available from 9 centers for a total
8,290 patients (52.6% of the entire cohort). CVD risk fac-
tors and complications were determined as part of the
baseline assessment using standardized protocols across
study centers.
CVD risk factors
All patients underwent a structured interview in order
to collect the following information: age, smoking status,
known diabetes duration, current glucose-, blood pres-
sure (BP)- and lipid-lowering treatments and anti-
platelet and anti-coagulant therapy, with indication of
the class of drug. Weight and height were assessed with
calculation of body mass index (BMI); BP was measured
with a sphygmomanometer after a 5 min of rest. Triglyc-
erides, total and HDL cholesterol were determined by
standard analytical methods; LDL cholesterol was calcu-
lated by the Friedwald formula. Hypertension was defined
as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg
and/or anti-hypertensive treatment. Dyslipidemia was de-
fined as high (≥100 mg/dl) LDL cholesterol and/or lipid-
lowering treatment.
Complications
Prevalent CVD at baseline was assessed from medical his-
tory by recording previous documented major acute CVD
events, including acute myocardial infarction (AMI),
stroke, foot ulcer or gangrene, amputation, coronary, ca-
rotid, and lower limb revascularization, and surgery for
Table 2 Complications and treatments in study subjects
Variables CVD no CVD yes P
n (%) 6,157 (74.3) 2,133 (25.7)
Albuminuria, mg/24
hours
60.6±275.6 125.6±554.8
<0.0001
12.6 (6.2-28.1) 17.4 (8.1-54.0)
Serum creatinine, μmol/l 82.2±31.8 94.6±39.8
<0.0001
77.8 (65.4-90.2) 85.7 (72.5-106.1)
eGFR MDRD, ml/min/1.73 m2 80.1±22.1 71.7±23.2
<0.0001
79.0 (66.3-92.9) 72.2 (55.9-86.8)
eGFR CKD-EPI,
ml/min/1.73 m2
81.8±19.4 71.7±21.5
<0.0001
84.4 (69.1-94.6) 74.8 (56.4-88.7)
Albuminuria <0.0001
Normoalbuminuria 4,687 (76.1) 1,366 (64.0)
Microalbuminuria 1,227 (19.9) 602 (28.2)
Macroalbuminuria 243 (3.9) 408 (7.7)
eGFR (MDRD) <0.0001
≥90 ml/min/1.73 m2 1,824 (29.6) 424 (19.9)
60–89 ml/min/1.73 m2 3,349 (54.4) 1,051 (49.3)
30–59 ml/min/1.73 m2 915 (14.9) 586 (27.5)
<30 ml/min/1.73 m2 69 (1.1) 72(3.4)
CKD phenotype <0.0001
no CKD 4,081 (66.3) 1,038 (48.7)
stages 1–2 CKD 1,092 (17.7) 437 (20.5)
stage ≥3 CKD
nonalbuminuric
606 (9.8) 328 (15.4)
stage ≥3 CKD
albuminuric
378 (6.1) 330 (15.5)
Retinopathy, n (%) <0.0001
No retinopathy 4,841 (78.6) 1,428 (66.9)
Non-advanced
retinopathy
841 (13.7) 429 (20.1)
Advanced
retinopathy
475 (7.7) 276 (12.9)
Any coronary event, n (%) — 1,373 (64.4) —
Acute myocardial
infarction, n (%)
— 949 (44.5)
—
Any cerebrovascular
event, n (%)
— 902 (42.3)
—
Stroke, n (%) — 257 (12.0) —
Any lower limb
vascular event, n (%)
— 584 (27.4)
—
Ulceration/gangrene, n (%) — 319 (15.0) —
Diabetes treatment, n (%) <0.0001
Diet 729 (11.8) 151 (7.1)
OHA 4,051 (65.8) 4,353 (59.9)
Insulin + OHA 570 (9.3) 205 (9.6)
Insulin 807 (13.1) 500 (23.4)
Lipid-lowering treatment,
n (%)
2,681 (43.5) 1,435 (67.3)
<0.0001
Table 2 Complications and treatments in study subjects
(Continued)
Anti-hypertensive
treatment, n (%)
4,232 (68.7) 1,850 (86.7)
<0.0001
ACE-I/ARB treatment,
n (%)
3,522 (57.2) 1,469 (68.9)
<0.0001
Prevalence of micro and macrovascular complications and type and rate of
treatments in individuals with or without prior CVD event(s). Values are mean±SD
and median (interquartile range) for continuous variables and n (%) for
categorical variables; P values for comparison between groups using the
Student’s t test for parametric or the corresponding Mann–Whitney U test for
nonparametric (albuminuria, serum creatinine and eGFR) continuous variables,
and the χ2 test for categorical variables.
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hospital discharge records or specialist visits by an ad hoc
committee in each center [26].
The presence of CKD at baseline was assessed by albu-
minuria and serum creatinine. As previously reported in
detail [27], albumin excretion rate (AER) was obtained
from timed (24 hour) urine collections or calculated from
albumin/creatinine ratio in early-morning, first-voided
urine samples, in the absence of symptoms and signs of
urinary tract infection or other interfering clinical condi-
tions. Albuminuria was measured in one-to-three fresh
urine samples for each patient by immunonephelometry or
immunoturbidimetry and, in case of multiple measure-
ments, the geometric mean was used for analysis. In sub-
jects with multiple measurements (4,062 with at least two
and 2,310 with three values), concordance rate between
the first value and the geometric mean was >90% for all
classes of albuminuria [27]. Patients were then assigned to
one of the following categories of albuminuria (mg/24
hours): normoalbuminuria (AER <30), microalbuminuria
(AER 30–299), or macroalbuminuria (AER ≥300). Serum
(and urine) creatinine was measured by the modified Jaffe
method. One to three measurements were obtained for
each patients and eGFR was calculated by the four-variable
Modification of Diet in Renal Disease (MDRD) Study
equation, using the mean serum creatinine value in case of
multiple measures, as reported in previous publications
[27-29]. Patients were then assigned to one of the following
categories of eGFR (mL/min/1.73 m2): 1 (≥90); 2 (60–89);
3 (30–59); 4 (15–29); and 5 (<15). Finally, subjects were
classified as having no CKD or CKD stages 1–5, based on
the presence or absence of micro or macroalbuminuria
and the value of eGFR calculated by the MDRD Study
equation, according to the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative [30]. Patients
assigned to CKD stages (and GFR classes) 4 and 5 were
pooled together. As previously reported [29], CKD patients
were further classified as having one of the following CKD
phenotypes: albuminuria alone (stages 1–2 CKD), reduced
eGFR alone (stage ≥3 CKD without albuminuria), or both
(stage ≥3 CKD with albuminuria).
Table 3 HbA1c-values and measures of HbA1c-variability
Variable n (%) Current HbA1c, % HbA1c-MEAN, % HbA1c-SD, % HbA1c-CV, % Adj-HbA1c-SD, %
No CVD
6,157 (74.3)
7.57±1.36 7.63±1.19 0.59±0.48 7.57±5.52 0.52±0.42
7.42 (6.70-8.28) 7.49 (6.81-8.31) 0.46 (0.28-0.73) 6.06 (3.94-9.37) 0.40 (0.26-0.67)
Any coronary event
1,373 (16.6)
7.85±1.34 7.88±1.20 0.60±0.45 7.40±5.13 0.53±0.39
7.70 (6.92-8.57) 7.77 (7.02-8.59) 0.47 (0.29-0.74) 6.18 (3.95-9.22) 0.41 (0.26-0.66)
P <0.0001 <0.0001 0.194 0.821 0.140
Acute myocardial infarction
949 (11.4)
7.80±1.31 7.86±1.18 0.62±0.45 7.64±5.08 0.54±0.39
7.67 (6.92-8.51) 7.78 (7.05-8.53) 0.49 (0.31-0.77) 6.39 (4.13-9.44) 0.43 (0.27-0.67)
P <0.0001 <0.0001 0.004 0.068 0.003
Any cerebrovascular event
902 (10.9)
8,00±1.51 7.96±1.24 0.59±0.45 7.18±4.91 0.52±0.40
7.75 (7.02-8.73) 7.83 (7.12-8.64) 0.47 (0.28-0.72) 5.91 (3.74-8.92) 0.41 (0.25-0.64)
P <0.0001 <0.0001 0.956 0.103 0.672
Stroke
257 (3.1)
7.64±1.37 7.70±1.21 0.59±0.40 7.56±4.86 0.51±0.34
7.45 (6.61-8.43) 7.63 (6.75-8.45) 0.48 (0.30-0.74) 6.28 (4.25-9.40) 0.42 (0.27-0.64)
P 0.470 0.354 0.299 0.381 0.325
Any lower limb vascular event
584 (7.0)
8.02±1.45 8.02±1.19 0.64±0.50 7.68±5.34 0.56±0.45
7.85 (7.09-8.73) 7.92 (7.22-8.66) 0.50 (0.31-0.80) 6.32 (4.10-9.38) 0.45 (0.27-0.69)
P <0.0001 <0.0001 0.013 0.372 0.005
Ulceration/gangrene
319 (3.8)
7.93±1.55 8.01±1.25 0.71±0.58 8.49±5.93 0.62±0.51
7.67 (6.98-8.62) 7.88 (7.18-8.64) 0.54 (0.34-0.86) 6.76 (4.31-10.23) 0.48 (0.30-0.76)
P <0.0001 <0.0001 <0.0001 0.004 <0.0001
Current HbA1c, HbA1c-MEAN, HbA1c-SD, HbA1c-CV, and Adj-HbA1c-SD values in patients with any major acute CVD event by vascular bed (coronary, carotid and
lower limb) versus subjects without CVD. Values are mean±SD and median (interquartile range); P values for comparison between groups using the Student’s t
test for parametric or the corresponding Mann–Whitney U test for nonparametric (HbA1c-SD, HbA1c-CV, and Adj- HbA1c-SD) variables.
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fundoscopy. In each center, an expert ophthalmologist was
asked to fill in a standardized report format and to classify
DR into absent, mild, moderate or severe non-proliferative
DR, proliferative DR, and maculopathy, according to the
Global Diabetic Retinopathy Project Group [31]. Patients
were classified based on the actual fundus appearance or
the retinal disease condition which had eventually required
a previous photocoagulation or surgical treatment. Based
on the worst eye, patients with non-proliferative DR of mild
or moderate degree were classified as having non-advanced
DR, whereas those with severe non-proliferative DR or pre-
proliferative DR, proliferative DR, maculopathy, or blind-
ness were grouped into the advanced DR category [32].
HbA1c variability
HbA1c was measured in each center by high performance
liquid chromatography using DCCT-aligned methods.
Average HbA1c and HbA1c variability were calculated for
each patient as the intra-individual mean (HbA1c-MEAN)
and SD (HbA1c-SD), respectively, for HbA1c values
obtained during the 2-year period preceding recruitment,
including that obtained at the enrolment. The inter-
individual difference in the number of HbA1c assessments
(a few values would make the SD apparently greater thanmany values) was adjusted according to the formula: adj-
HbA1c-SD = SD/√[n/(n-1)] [9,11]. Furthermore, as a nor-
malized measure of variability, the coefficient of variation
of HbA1c (HbA1c-CV) was calculated as the ratio of
HbA1c-SD and HbA1c-MEAN to correct for larger SD due
to higher absolute values of HbA1c-MEAN [19].
Statistical analysis
Data are expressed as median (interquartile range, IQR)
and/or mean±SD, for continuous variables, and number of
cases and percentage for categorical variables. Patients
were stratified by previous major acute CVD event(s).
Continuous variables were compared by Student’s t test or
one-way ANOVA, for normally distributed variables, and
by Mann–Whitney U test or Kruskall-Wallis test, in case
of variables with a skewed distribution. Pearson chi-square
was applied to categorical variables.
Logistic regression analyses with backward variable se-
lection (probability for removal >0.10) were performed to
assess whether increments in HbA1c-MEAN (Model 1),
increments of HbA1c-MEAN and HbA1c-SD (Model 2),
and quartiles of both variables (Model 3) are independent
correlates of CVD complications as compared with no
CVD. Covariates were, age, BMI, gender, known disease
duration, smoking habits, triglycerides, HDL cholesterol,
Table 4 Independent correlates of any CVD event(s)
Variables Any CVD event
OR 95%CI P
Age, x year 1.018 1.011-1.024 <0.0001
Diabetes duration, x year 1.019 1.013-1.025 <0.0001
Gender, male 1.746 1.550-1.967 <0.0001
BMI, x unit - - -
Smoking <0.0001
No 1.0
Former 1.413 1.254-1.591 <0.0001
Current 1.156 0.986-1.354 0.074
Triglycerides, x 0.0113 mmol/l 0.999 0.999-1.000 0.040
HDL cholesterol, x 0.259 mmol/l 0.983 0.978-0.987 <0.0001
Dyslipidemia 1.713 1.470-1.997 <0.0001
Hypertension 2.054 1.699-2.484 <0.0001
Diabetes treatment, n (%) <0.0001
Diet 1.0
OHA 1.266 1.038-1.544 0.020
Insulin + OHA 1.228 0.942-1.601 0.128
Insulin 2.051 1.623-2.593 <0.0001
Albuminuria 0.052
Normoalbuminuria 1.0
Microalbuminuria 1.167 1.030-1.323 0.015
Macroalbuminuria 1.069 0.845-1.351 0.580
eGFR (MDRD) <0.0001
≥90 ml/min/1.73 m2 1.0
60–89 ml/min/1.73 m2 1.116 0.975-1.278 0.112
30–59 ml/min/1.73 m2 1.820 1.531-2.162 <0.0001
<30 ml/min/1.73 m2 2.278 1.541-3.367 <0.0001
Retinopathy <0.0001
No retinopathy 1.0
Non advanced retinopathy 1.295 1.122-1.495 0.0001
Advanced retinopathy 1.298 1.084-1.554 0.005
MODEL 1
HbA1c-MEAN, 1% increment 1.062 1.011-1.114 0.016
MODEL 2
HbA1c -MEAN, 1% increment 1.062 1.011-1.114 0.016
HbA1c-SD, 1% increment - - -
MODEL 3
HbA1c-MEAN 0.001
quartile 1 1.0
quartile 2 0.923 0.787-1.082 0.322
quartile 3 1.248 1.066-1.462 0.006
quartile 4 1.096 0.928-1.295 0.281
HbA1c-SD quartiles – – –
Logistic regression analysis with backward variables selection of independent
correlates of any CVD event versus no CVD event. ORs of variables except HbA1c-
MEAN, HbA1c-SD, and their quartiles were determined by multivariate logistic
analysis from MODEL 1. The results did not change significantly in MODEL 2 and
MODEL 3.
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egories, CKD phenotype and DR stage, specific treatments
and either eGFR and albuminuria categories if DR was the
dependent variable, or DR categories if renal parameters
were the dependent variable. Results of these analyses
were expressed as odd ratios (ORs) with their 95% confi-
dence intervals (CIs). Logistic regression analyses s were
repeated entering adj-HbA1c-SD (or HbA1c-CV) instead of
HbA1c-SD as a measure of HbA1c variability.
All p values were two-sided, and a p value of less than
0.05 was considered statistically significant. Statistical
analyses were performed using SPSS version 13.0 (SPSS
Inc., Chicago, Illinois, USA).Results
Patients’ characteristics
As previously reported [23], participants included in this
analysis, i.e. those having multiple (3–5) HbA1c values,
had a median (IQR) age and duration of diabetes at enrol-
ment of 68 (61–74) and 14 (7–23) years, respectively, and
a male/female ratio of 57/43. Likely due to longer disease
duration, these subjects showed a worse CVD risk profile
and a higher prevalence of any CVD event and were more
frequently on glucose-, lipid- and BP-lowering drug treat-
ment, than those excluded from the analysis due to un-
availability of serial HbA1c measurements. HbA1c-MEAN
of participants was 7.57% (6.86-8.38), HbA1c-SD was 0.46
(0.29-0.74) and adj-HbA1c-SD was 0.40 (0.25-0.65). Both
variability measures, i.e. HbA1c-SD and adj-HbA1c-SD,
were closely related to HbA1c-MEAN and between each
other.
One or more major acute CVD events were adjudicated
in 2,133 of the 8,290 patients analyzed (25.7%). Clinical
characteristics of subjects with or without prior CVD
event(s) are shown in Tables 1 and 2. As compared with
individuals without CVD, patients with prior event(s) were
older, predominantly male, and had a longer diabetes dur-
ation, a worse metabolic control, a significantly higher rate
of insulin treatment, and a slightly but significantly higher
number of HbA1c measures (4.63±0.70 versus 4.48±0.78,
P<0.0001). Concerning the other CVD risk factors, these
patients were more frequently treated for dyslipidemia
and/or hypertension and had higher triglycerides and
lower HDL cholesterol, but also lower total, LDL and
non-HDL cholesterol and (marginally) BP levels. Finally,
subjects with prior CVD event(s) showed a higher preva-
lence of DR, albuminuria, reduced eGFR and CKD.Average HbA1c and HbA1c variability
As previously reported [23], increasing HbA1c-MEAN
and HbA1c-SD (or HbA1c-CV) were associated with lon-
ger and shorter diabetes duration, respectively, whereas
both measures correlated with a more adverse CVD risk
Table 5 Independent correlates of coronary events
Variables Any coronary event AMI
OR 95% CI P OR 95% CI P
Age, x year 1.015 1.007-1.023 0.003 1.025 1.015-1.034 <0.0001
Diabetes duration, x year 1.019 1.012-1.026 <0.0001 1.013 1.004-1.021 0.002
Gender, male 2.066 1.792-2.382 <0.0001 2.493 2.103-2.956 <0.0001
BMI, x unit — — — — — —
Smoking <0.0001 <0.0001
No 1.0 1.0
Former 1.496 1.301-1.719 <0.0001 1.560 1.327-1.834 <0.0001
Current 1.125 0.930-1.361 0.226 1.116 0.890-1.400 0.343
Triglycerides, x 0.0113 mmol/l 3.177 2.436-4.144 <0.0001 4.297 2.994-6.116 <0.0001
HDL cholesterol, x 0.259 mmol/l 0.981 0.975-0.986 <0.0001 0.982 0.976-0.988 <0.0001
Dyslipidemia 2.076 1.710-2.521 <0.0001 2.431 1.911-3.092 <0.0001
Hypertension 0.999 0.998-1.000 0.012 — — —
Diabetes treatment, n (%) <0.0001 <0.0001
Diet 1.0 1.0
OHA 1.205 0.953-1.524 0.119 1.302 0.988-1.716 0.061
Insulin + OHA 1.342 0.985-1.828 0.062 1.870 1.326-2.636 <0.0001
Insulin 2.013 1.528-2.652 <0.0001 2.444 1.786-3.345 <0.0001
Albuminuria <0.0001 — — —
Normoalbuminuria 1.0
Microalbuminuria 1.405 1.187-1.665 <0.0001
Macroalbuminuria 1.146 0.839-1.565 0.390
eGFR (MDRD) <0.0001 <0.0001
≥90 ml/min/1.73 m2 1.0 1.0
60–89 ml/min/1.73 m2 1.133 0.963-1.333 0.131 1.196 0.984-1.455 0.072
30–59 ml/min/1.73 m2 1.949 1.592-2.388 <0.0001 2.018 1.591-2.560 <0.0001
<30 ml/min/1.73 m2 1.731 1.087-2.757 0.021 1.714 1.005-2.924 0.048
Retinopathy 0.016 0.049
No retinopathy 1.0 1.0
Non advanced retinopathy 1.229 1.037-1.457 0.017 1.221 1.001-1.489 0.048
Advanced retinopathy 1.255 1.018-1.547 0.033 1.260 0.991-1.603 0.060
MODEL 1
HbA1c-MEAN, 1% increment 1.069 1.010-1.133 0.022 – – –
MODEL 2
HbA1c-MEAN, 1% increment 1.069 1.010-1.133 0.022 – – –
HbA1c-SD, 1% increment – – – – – –
MODEL 3
HbA1c-MEAN 0.004 0.003
quartile 1 1.0 1.0
quartile 2 0.961 0.793-1.163 0.680 0.956 0.763-1.197 0.692
quartile 3 1.297 1.073-1.567 0.007 1.68 1.097-1.706 0.005
quartile 4 1.159 0.950-1.414 0.146 1.075 0.849-1.360 0.549
HbA1c-SD quartiles – – – – – –
Logistic regression analysis with backward variables selection of independent correlates of any coronary event and acute myocardial infarction (AMI) versus no
CVD. ORs of variables except HbA1c-MEAN, Hb-A1c-SD and their quartiles were determined by multivariate logistic analysis from MODEL 1. The results did not
change significantly in MODEL 2 and MODEL 3.
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Table 6 Independent correlates of cerebrovascular events
Variables Any cerebrovascular event Stroke
OR 95% CI P OR 95% CI P
Age, x year 1.022 1.012-1.032 <0.0001 1.046 1.030-1.062 <0.0001
Diabetes duration, x year 1.033 1.025-1.042 <0.0001 – – –
Gender, male 1.720 1.452-2.036 <0.0001 2.041 1.520-2.739 <0.0001
BMI, x unit 1.016 1.000-1.033 0.046 – – –
Smoking 0.060 0.020
No 1.0 1.0
Former 1.196 1.010-1.416 0.030 1.446 1.081-1.935 0.013
Current 1.216 0.976-1.516 0.081 1.503 1.030-2.194 0.034
Triglycerides, x 0.0113 mmol/l 1.520 1.158-1.995 0.003 2.269 1.348-3.819 0.002
HDL cholesterol, x 0.259 mmol/l 0.983 0.977-0.989 <0.0001 0.987 0.977-0.998 0.017
Dyslipidemia 1.780 1.424-2.224 <0.0001 1.644 1.125-2.402 0.010
Hypertension – – – – – –
Diabetes treatment, n (%) <0.0001 <0.0001
Diet 1.0 1.0
OHA 1.176 0.881-1.570 0.272 1.339 0.808-2.218 0.257
Insulin + OHA 0.611 0.402-0.927 0.021 1.756 0.938-3.297 0.080
Insulin 1.911 1.375-2.657 <0.0001 3.541 2.074-6.046 <0.0001
Albuminuria <0.0001 – – –
Normoalbuminuria 1.0
Microalbuminuria 1.405 1.187-1.665 <0.0001
Macroalbuminuria 1.146 0.839-1.565 0.390
eGFR (MDRD) <0.0001 0.001
≥90 ml/min/1.73 m2 1.0 1.0
60–89 ml/min/1.73 m2 1.126 0.211.376 0.247 1.394 0.963-2.018 0.078
30–59 ml/min/1.73 m2 1.747 1.367-2.233 <0.0001 1.817 1.167-2.830 0.008
<30 ml/min/1.73 m2 2.759 1.718-4.431 <0.0001 3.798 1.868-7.721 <0.0001
Retinopathy <0.0001 – – –
No retinopathy 1.0
Non advanced retinopathy 1.458 1.207-1.762 <0.0001
Advanced retinopathy 1.089 0.840-1.411 0.521
MODEL 1
HbA1c-MEAN, 1% increment 1.096 1.026-1.171 0.007 – – –
MODEL 2
HbA1c-MEAN, 1% increment 1.096 1.026-1.171 0.007 — — —
HbA1c-SD, 1% increment — — — — — —
MODEL 3
HbA1c-MEAN 0.002 — — —
quartile 1 1.0
quartile 2 00.981 0.776-1.241 0.874
quartile 3 1.410 1.116-1.781 0.004
quartile 4 1.325 1.029-1.707 0.029
HbA1c-SD quartiles – – – – – –
Logistic regression analysis with backward variables selection of independent correlates of any cerebrovascular event and stroke versus no CVD. ORs of variables
except HbA1c-MEAN, Hb-A1c-SD and their quartiles were determined by multivariate logistic analysis from MODEL 1. The results did not change significantly in
MODEL 2 and MODEL 3.
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Table 7 Independent correlates of lower limb vascular events
Variables Any lower limb vascular event Ulceration/gangrene
OR 95% CI P OR 95% CI P
Age, x year 1.025 1.013-1.037 <0.0001 1.033 1.017-1.048 <0.0001
Diabetes duration, x year 1.033 1.023-1.043 <0.0001 1.024 1.011-1.037 <0.0001
Gender, male 1.727 1.408-2.118 <0.0001 1.448 1.123-1.866 0.004
BMI, x unit – – – – – –
Smoking 0.008 – – –
No 1.0
Former 1.347 1.100-1.650 0.004
Current 1.317 1.010-1.718 0.042
Triglycerides, x 0.0113 mmol/l 1.385 1.005-1.909 0.047 – – –
HDL cholesterol, x 0.259 mmol/l 0.979 0.972-0.987 <0.0001 0.985 0.976-0.994 0.001
Dyslipidemia 1.557 1.201-2.018 0.001 – – –
Hypertension – – – – – –
Diabetes treatment, n (%) <0.0001 <0.0001
Diet 1.0 1.0
OHA 1.274 0.871-1.861 0.212 1.828 1.023-3.266 0.042
Insulin + OHA 1.146 0.710-1.848 0.577 1.669 0.845-3.296 0.140
Insulin 2.014 1.321-3.072 0.001 2.948 1.595-5.449 0.001
Albuminuria <0.0001 <0.0001
Normoalbuminuria 1.0 1.0
Microalbuminuria 1.527 1.248-1.868 <0.0001 1.878 1.447-2.436 <0.0001
Macroalbuminuria 1.375 0.967-1.957 0.076 2.053 1.351-3.119 0.001
eGFR (MDRD) <0.0001 <0.0001
≥90 ml/min/1.73 m2 1.0 1.0
60–89 ml/min/1.73 m2 1.221 0.947-1.574 0.124 1.195 0.851-1.678 0.303
30–59 ml/min/1.73 m2 2.187 1.626-2.942 <0.0001 2.104 1.430-3.097 <0.0001
<30 ml/min/1.73 m2 2.001 1.107-3.618 0.022 2.059 1.018-4.165 0.044
Retinopathy <0.0001 <0.0001
No retinopathy 1.0 1.0
Non advanced retinopathy 1.696 1.353-2.125 <0.0001 1.880 1.403-2.520 <0.0001
Advanced retinopathy 1.892 1.439-2.489 <0.0001 2.680 1.926-3.729 <0.0001
MODEL 1
HbA1c-MEAN, 1% increment 1.086 1.003-1.175 0.042 – – –
MODEL 2
HbA1c-MEAN, 1% increment 1.086 1.003-1.175 0.042 – –
HbA1c-SD, 1% increment 1.208 0.974-1.497 0.085 1.407 1.134-1.746 0.036
MODEL 3
HbA1c-MEAN 0.026 – – –
quartile 1 1.0
quartile 2 1.075 0.800-1.445 0.632
quartile 3 1.466 1.101-1.953 0.009
quartile 4 1.296 0.967-1.737 0.083
HbA1c-SD quartiles – – – 0.036
quartile 1 1.0
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Table 7 Independent correlates of lower limb vascular events (Continued)
quartile 2 1.057 0.736-1.518 0.764
quartile 3 – 1.018 0.709-1.462 0.922
quartile 4 1.498 1.061-2.116 0.022
Logistic regression analysis with backward variables selection of independent correlates of any lower limb vascular event and ulceration/gangrene versus no CVD.
ORs of variables except HbA1c-MEAN, Hb-A1c-SD and their quartiles were determined by multivariate logistic analysis from MODEL 1. The results did not change
significantly in MODEL 2 and MODEL 3.
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treatment, with a few differences.
Values for current HbA1c, HbA1c-MEAN, HbA1c-SD,
HbA1c-CV and Adj-HbA1c-SD in subjects with or with-
out any major acute CVD event are given in Tables 1
(total) and 3 (by vascular bed, i.e. coronary, carotid and
lower limb). As compared with men, women showed
significantly higher values of current HbA1c (7.75±1.40
versus 7.58±1.32, P<0.0001), HbA1c-MEAN (7.80±1.24
versus 7.62±1.17, P<0.0001) and lower levels of HbA1c-
SD (0.59±0.49 versus 0.60±0.47, P=0.049), HbA1c-CV
(7.39±5.50 versus 7.65±5.38, P=0.001), and, non-
significantly, Adj-HbA1c-SD (0.52±0.43 versus 0.52±0.40,
P=0.060), as compared with men. When stratified by pres-
ence or absence of any CVD event, total and by vascular
bed, data in men and women were almost identical to
those from the whole cohort presented in Table 3 (Add-
itional file 2: Tables S1-S2). Current HbA1c and HbA1c-
MEAN were higher in patients with history of any CVD,
either total or by vascular bed, whereas HbA1c-SD and
Adj-HbA1c-SD were significantly increased in subjects
with AMI, any lower limb vascular event and ulceration/
gangrene and HbA1c-CV only in those with this latter
event. Current HbA1c and HbA1c-MEAN values, but not
measures of HbA1c variability, increased with the number
of major acute CVD events and with the number of vascu-
lar beds affected (P<0.0001). However, while these values
did not change significantly with increasing number of
events (from 1 to ≥5), they were higher in subjects with 2
or 3 vascular beds affected than in those with involvement
of only one site.
Multiple logistic regression models
We used logistic models as multivariate regression ana-
lyses because of several potential confounding factors for
the association between HbA1c variability and prevalence
of macrovascular complications. Even after adjusting for
CVD risk factors and complications, HbA1c-MEAN, but
not HbA1c-SD (and independent of it in Models 2 and 3)
was a significant correlate of any CVD (Table 4).
When CVD was examined by vascular bed, similar find-
ings were observed in subjects with versus those without
any coronary event (AMI and/or coronary revasculariza-
tion) or any cerebrovascular event (stroke and/or carotid
revascularization) in all 3 models (Tables 5 and 6) and in
those with versus without AMI in Model 3 only (Table 5).Conversely, none of these measures were associated with
stroke (Table 6), whereas both correlated with any lower
limb vascular event (ulceration/gangrene and/or lower
limb revascularization; Hb-A1c-SD only in Model 2) and
HbA1c-SD alone with ulceration/gangrene (Table 7).
In all models, expressing HbA1c variability as HbA1c-CV
or adj-HbA1c-SD instead of HbA1c-SD did not change the
results.
Discussion
Recently, microvascular complications were shown to be
predicted by HbA1c variability from one visit to the next,
independently of average HbA1c and known risk factors
for microangiopathy, both in type 1 [18-20] and type 2
[21-23] diabetes. Less clear is the relation of HbA1c vari-
ability with CVD. This cross-sectional analysis did not
show a significant association of CVD with HbA1c vari-
ability, whereas events were independently associated
with average HbA1c. However, we did also analyze acute
major CVD events occurring in different vascular beds
and found significant differences in their relation with
HbA1c variability versus average HbA1c.
The correlation of average HbA1c with CVD is consist-
ent with data from large trials [5,6]; this correlation was
observed in both sexes, though women had higher average
HbA1c values than men, in keeping with previous reports
[33,34]. Conversely, the lack of association of HbA1c vari-
ability with total CVD events (as well as with any coronary
or cerebrovascular events, AMI or stroke) is at variance
with results of previous longitudinal studies in Finnish in-
dividuals with type 1 diabetes [19] and subjects with type
2 diabetes from the Hong Kong Diabetes Registry [25].
Though this discrepancy might be explained by differences
in type of diabetes or ethnicity, it is more likely attribut-
able to the much lower HbA1c variability observed in our
cohort, as compared with these previous reports. In fact,
HbA1c-SD values were 0.47 and 0.46 in subjects without
and with CVD, respectively, versus 0.79 and 0.87 in the
type 1 Finnish cohort [19] and 1.1 and 1.4 in the type 2
Chinese cohort [25]. Conversely, HbA1c-MEAN values in
our cohort (7.5 and 7.8, respectively) were similar to those
found in subjects from the Hong Kong Diabetes Registry
(7.4 and 7.8, respectively) [25]. Thus, it might be hypothe-
sized that the contribution of small changes in HbA1c
values from one visit to the next is negligible and that the
impact of average HbA1c would be predominant under
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creased risk. In this view, the results of our study may not
be in contrast with those of the above-mentioned reports
[19,25]; however, if we consider that such a small variabil-
ity of HbA1c was significantly associated with CKD (espe-
cially albuminuric), but not DR [23], we might conclude
that DN is the most sensitive complication to changes in
HbA1c, whereas CVD and DR are influenced by wider
fluctuations of this parameter over time.
The diverging correlation of acute major CVD events oc-
curring in different vascular beds with HbA1c variability
versus average HbA1c might reflects distinct characteristics
of vascular disease at these levels. In particular, multiple
mechanisms contribute to various extent to the develop-
ment of ulceration/gangrene, including macroangiopathy,
but also microvascular disease and neuropathy. This might
explain the fact that both average Hb-A1c and Hb-A1c vari-
ability were associated with lower limb vascular event(s)
(including also lower limb revascularization) and particu-
larly the correlation of Hb-A1c variability, but not average
Hb-A1c, with ulceration/gangrene alone. This finding is
also consistent with our previous report that the independ-
ent association of reduced eGFR with coronary events is
stronger than that with peripheral events, which are related
predominantly with the albuminuric CKD phenotypes
reflecting predominantly microvascular disease [26].
Strengths of this study include the large size of the co-
hort, the completeness of data, the analysis of a contem-
porary dataset, the adjustment for treatments, and, as
mentioned above, the analysis by vascular bed. The main
limitation is the cross-sectional design for the assess-
ment of prevalent CVD, which did not allow to examine
the effect of HbA1c.variability on the development of
macrovascular complications in uncomplicated individ-
uals, as in the studies of Waden et al. [19] and Luk et al.
[25]. Another limitation might be that the RIACE partic-
ipants who had serial (3–5) HbA1c measures differed sig-
nificantly (i.e. longer diabetes duration, worse CVD risk
profile, higher prevalence of any CVD event, and higher
rate of treatment) from those who did not and were
therefore excluded from this analysis. Thus, though virtu-
ally all subjects from the 9 centers which made available
these data had more than two HbA1c measures, independ-
ently of their HbA1c variability, we cannot rule out a selec-
tion bias. Other possible limitations concerning HbA1c
values are that they were performed in each center as a
part of the patient’s standard care with no pre-specified in-
tervals between HbA1c measurements, and that the num-
ber of measures per individual varied from 3 to 5.
However, non-centralized measurements did not affect
intra-individual variability, intervals between measure-
ments ranged from 6 to 9 months, and adj-HbA1c-SD was
used to account for difference in the number of measures.
Furthermore, though the number of measurements wasnot as large as in the study of Sugawara et al. [21] and the
period analyzed was not as long as in the study of Hsu
et al. [22], re-analyses of these surveys showed that using
3-monthly (i.e. 4 to 5) HbA1c measurements [21] or a
series of 2-year HbA1c values [22], as in our study, did not
change the results. Finally, potential limitations concerning
non-centralized assessment of DN and DR have been
addressed in previous RIACE reports [27-29,32].
In conclusion, in patients with type 2 diabetes, HbA1c
variability has not a great impact on macrovascular com-
plications, at variance with average HbA1c, an opposite
finding as compared with microvascular disease, and par-
ticularly DN and especially albuminuric CKD phenotypes.
Additional files
Additional file 1: A complete list of the RIACE Investigators can be
found as Additional files 2.
Additional file 2: Table S1. HbA1c-values and measures of HbA1c-
variability in female subjects (n. 3,564). Current HbA1c, HbA1c-MEAN,
HbA1c-SD, HbA1c-CV, and Adj-HbA1c-SD values in patients with any major
acute CVD event by vascular bed (coronary, carotid and lower limb)
versus subjects without CVD. Table S2: HbA1c-values and measures of
HbA1c-variability in male subjects (n. 4,726). Current HbA1c, HbA1c-MEAN,
HbA1c-SD, HbA1c-CV, and Adj-HbA1c-SD values in patients with any major
acute CVD event by vascular bed (coronary, carotid and lower limb)
versus subjects without CVD.
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